The HER2 status assessment was originally standardised by The American Society of Clinical Oncology and the College of American Pathologists (ASCO/CAP) that published guidelines recommending to test HER2 protein overexpression by IHC and ERBB2 gene amplification by ISH using FFPE tumour tissue. Here, ERBB2 is linked to neoplasm.